The high prevalence of PD-L1 gene amplification and its association with clinical features and response to anti-PD-1 therapy has been well documented in cHL, non-small cell lung cancer and melanoma [20, 36, 37]. Here, CD274 is linked to non-small cell lung carcinoma.